Key result
A newly developed siloxane poly(urethane-urea) elastomer demonstrated excellent biostability, minimal thrombogenicity, and no adverse tissue response compared to standard tissue-based valves in preclinical models.
Why the study?
Synthetic polymer leaflets in prosthetic cardiac valves hold potential to reduce calcification and thrombus while improving blood flow, durability, and device economics.
Population
Preclinical models including ovine models and ex vivo AV shunts
Comparison
Prototype heart valves with LP leaflets vs clinically standard tissue-based valve
Design
Preclinical biocompatibility, ex vivo thrombogenicity, and in vivo animal study
Follow-up
24-week
Authors
Loading...
May support synthetic valve development; leaves open human trials to confirm safety and durability.
A novel siloxane poly(urethane-urea) elastomer demonstrates excellent biocompatibility, low thrombogenicity, and high biostability in preclinical models, suggesting suitability for synthetic heart valve leaflets.
Jenney et al. (2020) studied Prosthetic cardiac valves. Siloxane poly(urethane-urea) elastomer (LifePolymer, LP) vs. Clinically standard tissue-based valve was evaluated on Biocompatibility, thrombogenicity, and systemic tissue response. A newly developed siloxane poly(urethane-urea) elastomer demonstrated excellent biostability, minimal thrombogenicity, and no adverse tissue response compared to standard tissue-based valves in preclinical models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: